Skip to main content
Indian stocks: Visit www.stage2stocks.com →

Quest Diagnostics Incorporated

Stage 2 · Advancing · week 17

As of Oct 22, 2026, Quest Diagnostics is in Stage 2, the uptrend phase, now in week 17 (since Jun 25, 2026). It closed at $243.28, 1.3% below its 52-week high and above its 200-day average, which is rising.

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. More about the company

$243.28
+1.82% today
$26.9B · Large cap
Market Neutral — Fading

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 32 in Diagnostics & Research · #1 of 272 in Health Care

Is DGX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 38w
S2 23w
S2 18w
S2 17w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 2w → S4 11w → S1 5w → S2 6w → S3 3w → S4 8w → S1 2w → S2 38w → S3 3w → S2 23w → S3 3w → S2 18w → S3 6w → S2 13w → S3 7w → S2 17w current
Total tracked: 166 weeks across 16 stage runs.

DGX among Diagnostics & Research13th of 44 by relative strength

All 44 →
Stocks in Diagnostics & Research ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CDNAStage 2 · wk 2499+27.3%
2BDSXStage 2 · wk 1898−18.3%
3ILMNStage 2 · wk 2497+5.5%
4GHStage 2 · wk 2197−7.6%
5NTRAStage 2 · wk 2096+2.7%
6CRLStage 2 · wk 1692+22.5%
7RVTYStage 2 · wk 1890+10.7%
8PSNLStage 2 · wk 1790−3.2%
…13DGXStage 2 · wk 1779+4.8%
vs 52W High
-1.3%
$170.62 lo$246.53 hi
Near 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 17
1w13w26w
Week 17, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
16.6%
200 DMA: $208.64 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
1.66x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+4.8%
3M
+7.2%
6M
+22.9%
YTD
+42.3%
1Y
+34.0%
Scan Membership
Breakout Watch
Latest: 2025-02-19
9 appearances in last 60 days. First seen: 2019-05-31.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 17 · Vol 1.66x
2026-10-21S2
Wk 17 · Vol 1.14x
2026-10-20S2
Wk 17 · Vol 1.10x
2026-10-19S2
Wk 17 · Vol 0.86x
2026-10-16S2
Wk 16 · Vol 0.80x
2026-10-15S2
Wk 16 · Vol 1.01x
2026-10-14S2
Wk 16 · Vol 1.22x
2026-10-13S2
Wk 16 · Vol 1.03x
2026-10-12S2
Wk 16 · Vol 0.88x
2026-10-09S2
Wk 15 · Vol 0.79x
2026-10-08S2
Wk 15 · Vol 0.96x
2026-10-07S2
Wk 15 · Vol 0.93x
Moving averages & range
50 DMA
$236.83
200 DMA
$208.64
52W High
$246.53
52W Low
$170.62
5D Low
$234.91
Resistance levels (recent highs)
20d High
$243.28
60d High
$246.53
120d High
$246.53
250d High
$246.53
Next resistance
+1.3%
to 60d High
P/E (TTM)
25.9
Forward 20.2
Earnings Growth (YoY)
+15.0%
Revenue +10.2%
ROE
+14.6%
Profit margin +9.2%
Dividend Yield
1.44%
P/B 3.6

Quest Diagnostics: quick answers

What stage is Quest Diagnostics in?

As of Oct 22, 2026, Quest Diagnostics (DGX) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 25, 2026 and is in week 17. What the four stages mean

Is Quest Diagnostics in an uptrend?

Yes. Quest Diagnostics is in a Stage 2 uptrend. It trades 16.6% above its 200-day average, which is rising.

How far is Quest Diagnostics from its 52-week high?

Quest Diagnostics closed at $243.28 on Oct 22, 2026, 1.3% below its 52-week high of $246.53. Its 52-week low is $170.62.

How has Quest Diagnostics performed over the past year?

As of Oct 22, 2026, Quest Diagnostics is up 34.0% over the past year and up 42.3% so far in 2026.

Which sector and industry is Quest Diagnostics in?

Quest Diagnostics is in the Diagnostics & Research industry, part of the Health Care sector.

About this companyHealth Care· Diagnostics & Research

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.